Healthcare

The money funds two different businesses at once: quick commerce shelves and a community of 7,000 physiotherapists. Only one of them is defensible.

Four years old, valued at ₹7.6 crore, with rivals raising three times that in a single round. The thesis underneath it is better than the numbers suggest.

The markups are the contested line in Indian health claims. Insurers have the data to see them and have lacked the regulatory basis to refuse them.

More than 10,000 clients and just over 400 surgeries in nine months. The first centre covers its running costs, which is not the same as having paid for itself.

The firm expects more than half its exits to come through listings, a departure from earlier funds that leaned on strategic sales and secondaries.

Qualcomm Ventures leads, with Labcorp and Alpha Wave joining. The profit figures everyone is citing come from the year before Ultrahuman lost half its revenue base.

Equentis led a $2 million pre-Series A into a company that supplies fulfilment to 30-plus health platforms. It wants 100 licensed dark stores in 50 cities.

Info Edge Ventures led ₹20 crore into a Gurugram company that was already profitable on ₹13 crore of revenue. It is the first institutional money in sixteen years.

The Hyderabad CRDMO's draft papers show FY26 revenue of ₹2,178.39 crore and 591 customers. Goldman Sachs and Quadria Capital are among its existing backers.

The Y Combinator-backed diagnostics platform grew revenue 65% in FY26 while its loss widened to ₹146 crore. The company says its home market of Bengaluru is now EBITDA-profitable.

The paediatric behavioural health platform will use the round to expand beyond Maharashtra and scale its Get SET Early autism screening tool. Its valuation and round terms were not disclosed.

The health-tech platform raised the round to expand its Sunshine by LISSUN child development centres and build AI-led tools. Terms beyond the headline amount were not disclosed.

Tenet Diagnostics has raised about $30 million led by Tata Capital's third healthcare fund. Its last public revenue figure is a target from 2023.

The Bengaluru medtech startup makes portable screening devices for diabetic-foot complications. The round funds commercialisation and manufacturing, but the company has not disclosed revenue or a valuation.

The Noida-based startup has raised its Series A from three funds, two of them returning seed backers, to build a foundational model for claims fraud. No lead investor or valuation was disclosed.

The platform lets hospitals deploy and monitor medical imaging AI from many vendors through one integration. It hosts more than 300 applications from over 100 vendors and serves 30 hospitals.

The company's CEREBO device uses near-infrared spectroscopy and machine learning to detect intracranial bleeding without radiation. It has held Indian regulatory clearance since 2023.

Accel, Elevation Capital and Nexus Venture Partners have backed Plazza’s attempt to combine neighbourhood pharmacies with localised inventory planning. The harder test will be whether deeper availability can justify the working capital and operating cost of a rapid store rollout.

The Bengaluru-based startup has secured fresh capital to scale its preventive health platform, utilizing a proprietary AI memory layer to bring affordable, personalised wellness coaching to India’s smaller cities.

The Bengaluru and Cambridge-based biotech firm has secured fresh capital to complete Phase 1 trials for its novel Natural Killer (NK) cell checkpoint inhibitor targeting solid tumors.

By combining physical neighborhood clinics with digital growth-tracking tools, the Bengaluru-based startup is capturing high-LTV, recurring revenue streams previously monopolized by traditional multi-specialty hospitals.

By leveraging its localized GMP manufacturing infrastructure, the Bengaluru-based biotechnology firm is successfully compressing the $500,000 cost of global CAR-T treatments into an affordable, indigenously built cell therapy for emerging markets.

India's largest drugmaker leverages a heavy debt structure to acquire the Merck spinoff, securing immediate dominance in women's health and a powerful foothold in the lucrative biosimilars market.

The Mumbai-based private equity firm has exceeded its initial $250 million target, drawing heavy commitments from global institutional investors to deploy capital across India's growing healthcare delivery and pharma manufacturing sectors.